Compare EDRY & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDRY | XLO |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.6M | 49.8M |
| IPO Year | 2018 | 2021 |
| Metric | EDRY | XLO |
|---|---|---|
| Price | $23.55 | $8.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 20.5K | ★ 32.1K |
| Earning Date | 06-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | $28.30 | N/A |
| Revenue Next Year | $10.13 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $7.64 | $0.46 |
| 52 Week High | $24.00 | $9.25 |
| Indicator | EDRY | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 64.02 | 53.90 |
| Support Level | $11.73 | $0.62 |
| Resistance Level | N/A | $9.03 |
| Average True Range (ATR) | 1.32 | 0.49 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 88.96 | 51.88 |
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.